Global Artificial Intelligence Drug R&D Market Strategic Research Report

Scope of the Report

The global Artificial Intelligence Drug R&D market size is predicted to grow from US$ 714 million in 2025 to US$ 1,295 million in 2032; it is expected to grow at a CAGR of 8.4% from 2026 to 2032.

Artificial Intelligence Drug R&D (AI Drug Development) refers to a class of R&D methods and software/platform systems that utilize technologies such as machine learning, deep learning, generative models, and knowledge graphs to model and infer multi-omics and biomedical data throughout the entire drug development process, from target discovery to lead compounds, preclinical trials, clinical trials, and post-marketing. This aims to improve the accuracy of target selection, shorten the candidate drug discovery cycle, reduce the failure rate, and optimize trial design and patient stratification.

AI-driven drug development is transitioning from "proof of concept" to "deliverable productivity." On one hand, large pharmaceutical companies and platform companies are emphasizing interpretability, auditability, and compliance (GxP/data governance), embedding AI models into existing experimental automation, LIMS/ELN, cheminformatics, and clinical operations systems to form an "AI + experimental closed loop" (design–make–test–analyze). On the other hand, industry focus is shifting from single-point tools to end-to-end capabilities: for example, integrating target selection, molecular generation, ADMET, and clinical strategies, while enhancing model generalization capabilities through multimodal data (omics, imaging, EHR, literature, and patents), making AI more closely aligned with real-world R&D decisions.

Simultaneously, generative AI is reshaping the workflow of early-stage research and translational medicine: at the molecular and protein level, the combination of generation and screening (virtual screening + de novo design) is becoming more common; at the clinical level, real-world data and patient stratification are driving "more precise enrollment and endpoint selection" to reduce trial size or increase success rates. In terms of commercialization, the cooperation model has expanded from "software subscription" to "milestone/revenue sharing, joint R&D, and joint pipeline incubation", and places greater emphasis on quantifiable deliverables (hit rate, shortened cycle, candidate quality) and reproducible verification system.

This report presents a comprehensive overview of the global Artificial Intelligence Drug R&D market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Software
• Service

Segment by Stage

• Target Identification & Validation
• Hit/Lead Discovery
• Clinical Development & Trial Design
• Others

Segment by Technology

• Machine Learning & Deep Learning
• Generative Models
• Knowledge Graph & NLP
• Multi-omics / Multimodal Modeling

Segment by Application

• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations（CRO)
• Academic & Research Institutions
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Artificial Intelligence Drug R&D market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations（CRO) evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact